(Q42660768)

4 November 2017

Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density (English)

1 reference

4 November 2017

Christian Muschitz

1

1 reference

4 November 2017

Roland Kocijan

2

1 reference

4 November 2017

Astrid Fahrleitner-Pammer

3

1 reference

4 November 2017

Solveig Lung

4

1 reference

4 November 2017

Heinrich Resch

5

1 reference

4 November 2017

1 January 2013

1 reference

Journal of Bone and Mineral Research

4 November 2017

1 reference

4 November 2017

28

1 reference

4 November 2017

196-205

1 reference

4 November 2017

1

1 reference

Update of current therapeutic options for the treatment of postmenopausal osteoporosis

4 November 2017

1 reference

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy

21 January 2018

1 reference

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium

21 January 2018

1 reference

Present at the beginning: a personal reminiscence on the history of teriparatide.

21 January 2018

1 reference

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

The use of parathyroid hormone in the treatment of osteoporosis

21 January 2018

1 reference

Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window

21 January 2018

1 reference

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis

21 January 2018

1 reference

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis

21 January 2018

1 reference

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

21 January 2018

1 reference

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 January 2018

1 reference

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

Effects of teriparatide retreatment in osteoporotic men and women

21 January 2018

1 reference

Daily and cyclic parathyroid hormone in women receiving alendronate

21 January 2018

1 reference

Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate

21 January 2018

1 reference

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 January 2018

1 reference

Vertebral fracture assessment using a semiquantitative technique.

21 January 2018

1 reference

Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy

21 January 2018

1 reference

Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment

21 January 2018

1 reference

Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis

21 January 2018

1 reference

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

21 January 2018

1 reference

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JBMR.1716

1 reference

4 November 2017

1 reference